Characterization of a Novel T Cell-Engaging Bispecific Antibody for Elimination of L1CAM-Positive Tumors

Scientists designed and characterized a novel bispecific antibody based on the IgG-(L)-ScFv format, which targeted L1CAM and CD3 simultaneously.